NBIX vs. SYK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at NBIX and SYK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | NBIX | SYK |
|---|---|---|
| Company Name | Neurocrine Biosciences, Inc. | Stryker Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 14.08 billion USD | 141.08 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | May 23, 1996 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of NBIX and SYK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | NBIX | SYK |
|---|---|---|
| 5-Day Price Return | -4.29% | -1.20% |
| 13-Week Price Return | 11.69% | -8.21% |
| 26-Week Price Return | 22.66% | -0.92% |
| 52-Week Price Return | 22.01% | 0.80% |
| Month-to-Date Return | 0.56% | -1.49% |
| Year-to-Date Return | 2.84% | 1.14% |
| 10-Day Avg. Volume | 0.93M | 1.81M |
| 3-Month Avg. Volume | 0.90M | 1.25M |
| 3-Month Volatility | 27.44% | 17.50% |
| Beta | 0.22 | 0.91 |
Profitability
Return on Equity (TTM)
NBIX
13.22%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, NBIX’s Return on Equity of 13.22% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
SYK
14.08%
Health Care Equipment & Supplies Industry
- Max
- 29.93%
- Q3
- 16.99%
- Median
- 9.28%
- Q1
- 5.10%
- Min
- -12.52%
SYK’s Return on Equity of 14.08% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
NBIX
13.88%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
NBIX’s Net Profit Margin of 13.88% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
SYK
12.25%
Health Care Equipment & Supplies Industry
- Max
- 24.41%
- Q3
- 13.71%
- Median
- 10.08%
- Q1
- 5.96%
- Min
- -5.58%
SYK’s Net Profit Margin of 12.25% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
NBIX
19.72%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
NBIX’s Operating Profit Margin of 19.72% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
SYK
15.18%
Health Care Equipment & Supplies Industry
- Max
- 31.09%
- Q3
- 18.11%
- Median
- 15.07%
- Q1
- 8.48%
- Min
- -0.28%
SYK’s Operating Profit Margin of 15.18% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | NBIX | SYK |
|---|---|---|
| Return on Equity (TTM) | 13.22% | 14.08% |
| Return on Assets (TTM) | 9.39% | 6.52% |
| Net Profit Margin (TTM) | 13.88% | 12.25% |
| Operating Profit Margin (TTM) | 19.72% | 15.18% |
| Gross Profit Margin (TTM) | 98.49% | 64.62% |
Financial Strength
Current Ratio (MRQ)
NBIX
3.20
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
NBIX’s Current Ratio of 3.20 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
SYK
1.78
Health Care Equipment & Supplies Industry
- Max
- 5.19
- Q3
- 3.00
- Median
- 2.13
- Q1
- 1.44
- Min
- 0.86
SYK’s Current Ratio of 1.78 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
NBIX
0.00
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
NBIX’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
SYK
0.70
Health Care Equipment & Supplies Industry
- Max
- 1.61
- Q3
- 0.76
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
SYK’s Debt-to-Equity Ratio of 0.70 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
NBIX
6.75
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
NBIX’s Interest Coverage Ratio of 6.75 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
SYK
14.59
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 25.56
- Median
- 9.60
- Q1
- 3.78
- Min
- -26.49
SYK’s Interest Coverage Ratio of 14.59 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | NBIX | SYK |
|---|---|---|
| Current Ratio (MRQ) | 3.20 | 1.78 |
| Quick Ratio (MRQ) | 3.10 | 0.88 |
| Debt-to-Equity Ratio (MRQ) | 0.00 | 0.70 |
| Interest Coverage Ratio (TTM) | 6.75 | 14.59 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
NBIX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
SYK
0.93%
Health Care Equipment & Supplies Industry
- Max
- 4.15%
- Q3
- 1.76%
- Median
- 0.79%
- Q1
- 0.00%
- Min
- 0.00%
SYK’s Dividend Yield of 0.93% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
NBIX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
SYK
42.87%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 66.60%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
SYK’s Dividend Payout Ratio of 42.87% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | NBIX | SYK |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.93% |
| Dividend Payout Ratio (TTM) | 0.00% | 42.87% |
Valuation
Price-to-Earnings Ratio (TTM)
NBIX
39.76
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
A P/E Ratio of 39.76 places NBIX in the upper quartile for the Biotechnology industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
SYK
46.25
Health Care Equipment & Supplies Industry
- Max
- 67.29
- Q3
- 47.01
- Median
- 30.94
- Q1
- 23.91
- Min
- 10.79
SYK’s P/E Ratio of 46.25 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
NBIX
5.52
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
NBIX’s P/S Ratio of 5.52 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
SYK
5.67
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.86
- Q1
- 2.07
- Min
- 0.74
SYK’s P/S Ratio of 5.67 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
NBIX
4.62
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
NBIX’s P/B Ratio of 4.62 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
SYK
7.13
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 6.56
- Median
- 3.53
- Q1
- 2.36
- Min
- 0.71
SYK’s P/B Ratio of 7.13 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | NBIX | SYK |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 39.76 | 46.25 |
| Price-to-Sales Ratio (TTM) | 5.52 | 5.67 |
| Price-to-Book Ratio (MRQ) | 4.62 | 7.13 |
| Price-to-Free Cash Flow Ratio (TTM) | 26.19 | 33.54 |